FDA Approves the First Generic Liraglutide – A Milestone in Type 2 Diabetes Treatment

On 23 December 2024, the United States Food and Drug Administration (FDA) approved the first generic of Victoza (liraglutide injection), 18 milligrams/3 milliliters. This glucagon-like peptide-1 (GLP-1) receptor agonist is used alongside diet and exercise to improve glycemic control in adults and children aged 10 years and older with type 2 diabetes.

A generic drug is an equivalent medicine produced after the original drug's patent expires, with the same active ingredient, dosage, safety, and efficacy characteristics, but usually at a lower cost. These medicines provide the same therapeutic benefit while expanding access to care and reducing costs.

GLP-1 Generics Are Beginning to Receive Approval

Last month, the FDA approved the first generic drug in the GLP-1 receptor agonist class. It was a generic equivalent of the original drug Byetta (exenatide). In other words, before generic liraglutide was approved, the first FDA-approved generic in the GLP-1 class was the generic version of Byetta. This highlights the FDA's ongoing efforts to bring generic medicines to market.

Liraglutide injection and certain other GLP-1 medicines are currently experiencing shortages in the United States. The FDA is prioritizing reviews of generic drug applications for medicines in shortage to help improve patients' access.

What Does This Development Offer?

The announcement reports FDA approval of the first generic formulation in the GLP-1 receptor agonist class used to treat type 2 diabetes. In particular, approval of generic liraglutide injection aims to ease the current supply shortage in this drug class and increase patients' access to more affordable treatment options.

Key Developments

1. Generic Drug Approval: The FDA approved a generic version of liraglutide, a GLP-1 receptor agonist used to treat type 2 diabetes. This provides a treatment option that will generally be available at a lower price.

2. Role in Type 2 Diabetes Treatment: Liraglutide improves blood sugar levels by mimicking the effects of GLP-1 in the pancreas. Approximately 38 million people in the United States have diabetes, and 90-95% of them have type 2 diabetes.

3. Drug Shortages and the Response: Given the current shortage of GLP-1 medicines, this approval is viewed as a step toward improving patients' access to treatment.

The Importance of Generic Medicines

In some cases, generic medicines are produced in limited numbers because of complex formulations and high development costs. By clarifying regulatory expectations for generic drug development and providing financial support, the FDA helps overcome these limitations.

According to the FDA's statement:

• Patients' Access to Treatment Will Increase: Generic medicines are generally offered at lower prices than original medicines, making treatment more widely accessible.
• Support for Research and Development: Research and development for generic medicines receives support, and manufacturers are given guidance at an early stage.

Risks and Side Effects

Considerations when using liraglutide:

• Risk of Thyroid Cancer: Because this medicine may increase the risk of thyroid C-cell tumors, it is not recommended for people with a history of thyroid cancer.
• Other Health Risks: Potential side effects include pancreatitis, kidney failure, gallbladder disease, and hypoglycemia.

Conclusion

This development represents an important step toward improving access to type 2 diabetes treatment. The FDA approval opens the door to more affordable treatment options for both patients and healthcare systems. However, the risks of using the medicine must be carefully assessed, and patient monitoring must remain a priority.